Nature Minikel, E V, Karczewski, K J, Martin, H C, Cummings, B B, Whiffin, N, Rhodes, D, Alföldi, J, Trembath, R C, van Heel, D A, Daly, M J, Alföldi, J, Armean, I M, Banks, E, Bergelson, L, Cibulskis, K, Collins, R L, Connolly, K M, Covarrubias, M, Cummings, B B, Daly, M J, Donnelly, S, Farjoun, Y, Ferriera, S, Francioli, L, Gabriel, S, Gauthier, L D, Gentry, J, Gupta, N, Jeandet, T, Kaplan, D, Karczewski, K J, Laricchia, K M, Llanwarne, C, Minikel, E V, Munshi, R, Neale, B M, Novod, S, O’Donnell-Luria, A H, Petrillo, N, Poterba, T, Roazen, D, Ruano-Rubio, V, Saltzman, A, Samocha, K E, Schleicher, M, Seed, C, Solomonson, M & Soto, J & Tiao, G & Tibbetts, K 2020, ' Evaluating drug targets through human loss-of-function genetic variation ', Nature, vol. 581, no. 7809, pp. 459-464 . https://doi.org/10.1038/s41586-020-2267-z